Some GEN editors were in sunny San Diego covering the hottest research, trends, and products from the American Association for Cancer Research meeting. We kick things off with news from America’s Finest City, particularly around the growing role of AI in oncology. Then we dive into two new research studies. In the first, scientists used CRISPR to identify genes in primary CD4+ T cells that promote or restrict HIV infection. The second study described engineered implantable liver constructs that could eventually serve as a stopgap for patients waiting for donor transplants. Finally, the acquisitions keep coming as Eli Lilly scoops up CAR T cell therapy developer Kelonia for $7B. Also, Revolution Medicines has shared some impressive data from a Phase III trial of its pancreatic cancer drug.
Listed below are links to the GEN stories referenced in this episode of Touching Base:
AACR 2026: A Video Update from San Diego
By Julianna LeMieux, PhD, and Damian Doherty, GEN, April 21, 2026
AACR 2026 Video Update: Cancer Research Edges Toward an AI-Driven Era
By Fay Lin, PhD, and Jonathan Grinstein, PhD, GEN, April 22, 2026
Using AI in Healthcare Ethically by Considering Humanity
By Corinna Singleman, PhD, IPM, November 18, 2025
10x Genomics Unveils Atera Spatial Platform at AACR Meeting
By Julianna LeMieux, PhD, GEN, April 19, 2026
CRISPR Screens Map Human T‑Cell Genes That Promote or Block HIV Infection
GEN, April 20, 2026
Synthetic Biology and Tissue Engineering Grow Liver Tissue In‑Body
GEN, April 20, 2026
StockWatch: Revolution’s Phase III Pancreatic Cancer Data Dazzles Investors, Analysts
By Alex Philippidis, GEN Edge, April 19, 2026
Lilly to Acquire Kelonia for Up to $7B, Expanding Cancer Cell Therapy Pipeline
By Alex Philippidis, GEN Edge, April 20, 2026
Touching Base Podcast
Hosted by Corinna Singleman, PhD
Behind the Breakthroughs
Hosted by Jonathan D. Grinstein, PhD
